Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618
This examiner grants 46% of resolved cases
Samantha Lee Mejias has 28 resolved cases in Art Unit 1618. The examiner's allowance rate is 46.4%, and the median days to allowance is 1431. The interview lift is 40.9%, suggesting that interviews are a strong strategy for applicants in Tech Center 1600. This 40.9% lift is a significant factor for the 28 resolved cases in this docket.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18834636 | THERAGNOSTIC FOLATE CONJUGATES | Non-Final OA | Merck Patent GmbH |
| 18731289 | Oxidative Cyclization Reagents for Chemoselective Tryptophan Bioconjugation | Non-Final OA | The Regents of the University of California |
| 17613351 | APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18284035 | CYCLIC DINUCLEOTIDE CONJUGATES AND RELATED METHODS OF USE THEREOF | Non-Final OA | The Regents of the University of Michigan |
| 17783939 | MYELOID CELL-TARGETED NANOPARTICLES AND RELATED COMPOSITIONS AND METHODS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18002761 | OXINE-CONTAINING CELL RADIOLABELLING AGENTS | Non-Final OA | KING'S COLLEGE LONDON |
| 17796494 | HIGH MOLECULAR WEIGHT HEPARIN COMPOSITIONS AND METHODS FOR DIAGNOSING, TREATING AND MONITORING EOSINOPHIL MEDIATED INFLAMMATORY DISEASES | Non-Final OA | University of Utah Research Foundation |
| 18032760 | PROINFLAMMATORY PRODRUGS | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 19234864 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | Final Rejection | Novartis AG |
| 18119456 | FLUORINE-CONTAINING COMPOUND AND CONTRAST AGENT | Non-Final OA | TDK Corporation |
| 17910248 | TARGETED NANOBUBBLE THERAPY | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18015807 | ASYMMETRIC CHARGED VESICLES AND METHODS OF PREPARING AND USE THEREOF | Non-Final OA | The Research Foundation for the State University of New York |
| 17635409 | LARGE SCALE PRODUCTION OF EXOSOME MIMETICS AND USES THEREOF | Non-Final OA | Children's Medical Center Corporation |
| 17007994 | CONJUGATED POLYCATIONIC POLYMERS, METHODS OF USING THE SAME AND METHODS OF TREATING AUTOIMMUNE DISEASES, INFECTIOUS DISEASES AND ACUTE RADIATION EXPOSURE | Final Rejection | Duke University |
| 17639469 | NANOPARTICLES FOR DETECTION OF BACTERIA CELLS AND METHODS OF PREPARATION THEREOF | Non-Final OA | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH |
| 17622580 | TRANSFECTION METHOD | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 17634897 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | Final Rejection | LONZA SALES AG |
| 18555983 | ORAL CARE FLAVOUR FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING | Non-Final OA | GIVAUDAN SA |
| 18556014 | ORAL CARE FLAVOUR FOR IMPROVING INVIGORATION STATE AND METHOD OF ASSESSING | Non-Final OA | GIVAUDAN SA |
| 18304987 | USE OF FOLIC ACID AND FOLATE MODIFICATION IN INDUCING B-CELL IMMUNE TOLERANCE AND TARGETING mIgM-POSITIVELY-EXPRESSED B-CELL LYMPHOMA | Non-Final OA | FUDAN UNIVERSITY |
| 17605869 | EYE DISEASE MARKER | Non-Final OA | SENJU PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy